Location History:
- Baltimore, MD (US) (2014 - 2017)
- San Francisco, CA (US) (2016 - 2021)
Company Filing History:
6 out of 3,688 
6 out of 2,010 
Years Active: 2014-2021
Title: **Innovative Insights from Inventor Xiaosong Zhang**
Introduction
Xiaosong Zhang is a renowned inventor based in San Francisco, CA, with a remarkable portfolio of six patents. His contributions to the field of genetics and oncology have garnered significant attention and recognition within the medical community.
Latest Patents
One of Xiaosong Zhang's latest patents focuses on genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma. He discovered mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas, as well as in glioblastomas that develop from these lower-grade lesions. Notably, tumors without mutations in IDH1 often harbored mutations at the analogous R172 residue of the closely related IDH2 gene. These groundbreaking findings carry critical implications for the pathogenesis and diagnosis of malignant gliomas.
Career Highlights
Throughout his career, Xiaosong Zhang has worked at prestigious institutions including The Johns Hopkins University and Duke University. His research has paved the way for advancements in understanding genetic mutations related to brain tumors, solidifying his position as a leading figure in genetic oncology.
Collaborations
Zhang has collaborated with notable scientists such as Bert Vogelstein and Kenneth W. Kinzler, further enhancing the quality and impact of his research. These collaborations have led to deeper insights into the genetic underpinnings of cancer, emphasizing the importance of teamwork in scientific discovery.
Conclusion
Xiaosong Zhang's contributions to the field of genetics, particularly in relation to malignant gliomas, exemplify the innovative spirit of modern invention. His discoveries not only advance scientific knowledge but also hold promise for the future of cancer diagnosis and treatment. With a strong foundation in research and collaboration, Zhang continues to be a pivotal figure in the ongoing quest for breakthroughs in oncology.